Keywords: UK, NICE, GlaxoSmithKline, Roche, Tyverb, Herceptin, Breast cancer

NICE views breast cancer drugs from GSK and Roche too expensive

Article | 14 February 2012

Print This

The UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) has published draft guidance today which proposes ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in